Shots: Merck acquires Immune Design, in all stock transaction for $5.85/share in cash making total deal value ~ $300M. The transaction is expected to close in Q2’19 The focus of […]readmore
Tags : Acquire
Shots: Novartis to receive $210M as total deal value, including $120M upfront, $60M deferred payment for 12mos. and $30M milestone on sales of product. Clinigen to get commercialization rights for […]readmore
Shots: J&J acquires Auris Health, in allstock transaction for $5.7B as total deal value, including $3.4B upfront in cash and $2.35B milestones. The transaction is expected to close in Q2’19 […]readmore
Shots: TeneoOne to receive $90M upfront and will take care of P-I trial for TNB-383B with its expected onset in H1’19. AbbVie to get exclusive WW rights to develop and […]readmore
Shots: Medtronic acquires EPIX Therapeutics, in all-stock transaction with its DiamondTemp Ablation system & Arctic Front Advance Cryoablation System. The acquisition is expected to close in Q4’19 i.e 26 Jan to 26 April, 2019 […]readmore
Shots: Abbott to acquire Cephea Valve, in all stock transaction, with its heart valve replacement technology The focus of the acquisition is to utilize Cephea’s technology in developing therapies for […]readmore
Shots: Eli Lily acquires Loxo Oncology, in all stock transaction for $8B. Loxo to receive $235/share in cash making $8B as total deal value, including premium based on its last […]readmore
Shots: BMS acquires Celgene, in all stock transaction for $74B. Celgene to receive $50/share, 1 BMS share and 1 Contingent Value Right (CVR) of $9 cash as regulatory milestone for […]readmore
Shots: Alcon acquires Tear Film in all stock transaction with its iLux device, used for the treatment of Meibomian Gland Dysfunction The focus of the acquisition is to strengthen and expand Alcon’s ocular […]readmore
Shots: GSK to acquire Tesaro, in all stock transaction with its Zejula and preclinical candidates. Tesaro to get $75/share in cash for a premium of 62% with total deal value […]readmore